AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial
The approach starts immunotherapy before a chemoembolization procedure to help keep tumors in check earlier.
Overview
- AstraZeneca said Thursday its phase 3 EMERALD-3 trial showed Imfinzi plus Imjudo with transarterial chemoembolization, a procedure that delivers chemotherapy into the tumor then blocks blood flow, produced a statistically significant and clinically meaningful gain in progression-free survival versus TACE alone.
- Analysts at JP Morgan and Citi now forecast peak annual sales near $11.3 billion for the combination following the top-line readout.
- An interim analysis signaled longer overall survival for the combination, with continued follow-up planned to confirm the trend and assess key secondary measures.
- The trial used one priming dose of Imjudo followed by regular Imfinzi, with or without lenvatinib, starting before TACE and continuing alongside the procedure.
- Investigators plan to present the results at an upcoming meeting, and the company will discuss potential use in this setting with regulators.